Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI
Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI
The purpose of this study is to compare DCB with DES in stable CAD or ACS patients who are at
 high risk of bleeding. Our hypothesis is that the strategy of using DCB and therefore shorter
 DAPT regimen is superior to the treatment using DES and longer DAPT in patients at high risk
 of bleeding.
Implantation of a drug-eluting stent (DES) has become a standard of percutaneous coronary
 intervention (PCI) during the last two decades. However there are still significant drawbacks
 in using DES as a permanent coronary implant. Most importantly, bleeding remains a
 significant complication of PCI, especially in elderly patients. The number of PCI patients
 having OAC:s is already significant, and will grow in the future, as the volume of PCIs in
 octogenarians increases, and so does the incidence of atrial fibrillation by age. After
 stenting at least one month lasting dual antiplatlet treatment (DAPT) is mandatory, and it
 cannot be safely terminated in case of a bleed. The optimal duration of DAPT on patients at
 bleeding risk is not known.

 Balloon coated with paclitaxel and iopromide (drug-coated balloon, DCB) was originally
 developed for the treatment of in-stent restenosis, but later its potential for the treatment
 of de-novo coronary artery leasons has become clear in large registry trials. So far, the
 randomized controlled studies have shown the non-inferiority of PCI using DCB in comparison
 to DES in de novo leasons in small vessels. Also the non-inferiority of PCI using DCB in
 comparison to BMS was shown in the DEBUT trial in large vessels on patients at high bleeding
 risk. These results need to be confirmed in comparison of DCB to DES as the use of BMS is
 diminishing.

 Our hypothesis in the DEBATE trial is that DCB and shorter DAPT regimen is superior to the
 treatment using DES and longer DAPT duration in the treatment of stable CAD or in ACS (UAP or
 NSTEMI) in patients on anticoagulation medication or otherwise on high bleeding risk.
Inclusion Criteria:

 -  Age ≥ 18 years

 -  Informed written consent

 -  At least one major or two minor bleeding risk criteria of Academic Research Consortium
 (ARC)

 Major Criteria

 -  Long-term oral anticoagulation

 -  Severe or end stage chronic kidney disease (CKD) (estimated glomerular - filtration
 rate [eGFR] <30 ml/min)

 -  Hemoglobin <110 g/l

 -  Spontaneous bleeding requiring hospitalization and transfusion in the past 6 months

 -  Moderate to severe baseline thrombocytopenia (platelet count <100 x 10e9/L)

 -  Chronic bleeding diathesis

 -  Liver cirrhosis with portal hypertension

 -  Active cancer in the past 12 months

 -  Previous spontaneous ICH (at any time)

 -  Previous traumatic ICH within the past 12 months

 -  Presence of known brain arteriovenous malformation

 -  Moderate to severe ischemic stroke within the past 6 months

 -  Nondeferrable major surgery on dual antiplatelet therapy

 -  Recent major surgery or trauma within 30 days before PCI

 Minor Criteria

 -  Age >75 years

 -  Moderate CKD (eGFR 30-59 ml/min)

 -  Hemoglobin 110-129 g/l for men and 110-119 g/l for women

 -  Spontaneous bleeding requiring hospitalization or transfusion within the past 12 -
 months not meeting major criterion

 -  Long term use of oral nonsteroidal antiinflammatory drugs or steroids

 -  Any ischemic stroke at any time not meeting major criterion

 Either of the following:

 1. Stabile angina or dyspnea and a coronary narrowing causing myocardial ischemia
 detected in the angiogram. In stable patients prior PCI, the evidence of ischemia is
 needed acquired either by perfusion imaging or by pressure wire measurement (FFR)
 during coronary angiography unless the coronary stenosis is > 90% in diameter.

 2. ACS (UAP or NSTEMI): symptoms of heart ischemia≥ 20 minutes and ≥ 0,5mm ST-depression
 or transient ST-elevation or T-wave inversion at least in two adjacent leads and/or a
 high sensitivity troponin (hs-tnt) rise at least one unit above the 99. percentil or
 at least 50% rise in hs-tnt between two samples taken 1-3 hours apart.

 At least one of the following:

 -  ≥1 de novo lesions in native coronary arteries or bypass vein grafts

 -  Reference diameter of the vessel is 2.0-5.0mm'

 -  Lesion length ≤ 40mm

 -  Lesion or lesions are suitable for PCI

 Exclusion Criteria:

 -  Inability to give written consent

 -  STEMI

 -  Reference diameter of the vessel is <2.0mm or >5.0 mm

 -  Bifurcation lesion requiring the stenting of either of the branches after
 predilatation (TIMI<3 or significant recoil >30% in the main epicardial vessel: LAD,
 LCX or RCA) after predilatation)

 -  Dissection affecting the flow (TIMI<3) or significant recoil (>30% in the main
 epicardial vessel: LAD, LCX or RCA) after predilatation

 -  in-stent restenosis

 -  Chronic total occlusion

 -  Life expectancy < 12 months

 -  Cardiogenic shock at the arrival to the coronary angiography

 -  Uncertainty about neurological recovery e.g. after resuscitation

 -  Need for bypass surgery by heart team decision